Trump seeks executive order to create board for controlling NIH research funding

Summary

President Trump has directed OMB Director Russ Vought to draft an executive order establishing a committee to oversee NIH research funding allocation Reuters. This move follows failed legislative attempts to cut the NIH budget by 40% and aims to shift decision-making power from scientific experts to government officials to align with ‘administration priorities’ .

Impact Analysis

So, Trump is basically executing a hostile takeover of the NIH checkbook. Since Congress blocked his ‘disastrous’ 40% budget cut earlier this year—even giving NIH a slight bump instead —the administration is now using executive orders to bypass the legislative branch entirely. By shifting funding decisions from expert scientists to a politically appointed committee, they’re effectively dismantling the peer-review system that has anchored U.S. biotech leadership for decades .

This isn’t just noise; we’re already seeing the damage. With over 5,700 projects already frozen or disrupted and 74,000 clinical trial participants affected, the predictability of the U.S. research pipeline is evaporating . For us, this means the ‘innovation premium’ for U.S.-based life sciences is at risk. Small-cap biotechs reliant on NIH grants for early-stage de-risking are now high-risk bets. Bottom line: expect a brain drain toward private-sector-funded hubs or international competitors. If you’re holding names with heavy academic partnerships, it’s time to re-evaluate their runway.